These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 16824027)
1. Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay. Hasegawa Y; Ando Y; Shimokata K Expert Rev Mol Diagn; 2006 Jul; 6(4):527-33. PubMed ID: 16824027 [TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic approach for cancer treatment-tailored medicine in practice. Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519 [TBL] [Abstract][Full Text] [Related]
3. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. Biason P; Masier S; Toffoli G J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239 [TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan. Ando M; Hasegawa Y; Ando Y Invest New Drugs; 2005 Dec; 23(6):539-45. PubMed ID: 16267624 [TBL] [Abstract][Full Text] [Related]
6. Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray. Tsunedomi R; Hazama S; Okayama N; Oka M; Nagano H Cancer Sci; 2017 Jul; 108(7):1504-1509. PubMed ID: 28474802 [TBL] [Abstract][Full Text] [Related]
7. Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. Dias MM; McKinnon RA; Sorich MJ Pharmacogenomics; 2012 Jun; 13(8):889-99. PubMed ID: 22676194 [TBL] [Abstract][Full Text] [Related]
8. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events]. Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029 [No Abstract] [Full Text] [Related]
9. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities. Fakih MG; Ross ME; Starostik P Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105 [TBL] [Abstract][Full Text] [Related]
10. [UGT1A1 Genotyping for Proper Use of Irinotecan]. Matsuoka A; Ando Y Rinsho Byori; 2015 Jul; 63(7):876-82. PubMed ID: 26591441 [TBL] [Abstract][Full Text] [Related]
11. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478 [TBL] [Abstract][Full Text] [Related]
12. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? Schulz C; Boeck S; Heinemann V; Stemmler HJ Anticancer Drugs; 2009 Nov; 20(10):867-79. PubMed ID: 19770637 [TBL] [Abstract][Full Text] [Related]
13. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer. Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135 [TBL] [Abstract][Full Text] [Related]
15. Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Hasegawa Y; Sarashina T; Ando M; Kitagawa C; Mori A; Yoneyama M; Ando Y; Shimokata K Clin Chem; 2004 Aug; 50(8):1479-80. PubMed ID: 15277366 [No Abstract] [Full Text] [Related]
16. [Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan]. Okazaki K; Watanabe T; Saito I; Murayama J Yakugaku Zasshi; 2012; 132(2):231-6. PubMed ID: 22293705 [TBL] [Abstract][Full Text] [Related]
17. [Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer]. Teruya T; Nakachi A; Shimabukuro N; Toritsuka D; Azuma Y; Hanashiro K; Nishiki T; Ota M; Shimabuku M; Shiroma H Gan To Kagaku Ryoho; 2015 May; 42(5):585-9. PubMed ID: 25981652 [TBL] [Abstract][Full Text] [Related]
18. Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients. Yan L; Wang XF; Wei LM; Nie YL; Liu JY; Zhang LR Int J Clin Pharmacol Ther; 2016 Mar; 54(3):193-9. PubMed ID: 26857783 [TBL] [Abstract][Full Text] [Related]
20. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]